Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
9.15
-0.48 (-4.98%)
At close: Jun 27, 2025, 4:00 PM
9.20
+0.05 (0.55%)
After-hours: Jun 27, 2025, 4:06 PM EDT
Daxor Revenue
In the year 2024, Daxor had annual revenue of $119.71K, down -26.75%. Daxor had revenue of $47.96K in the half year ending December 31, 2024, a decrease of -50.25%.
Revenue (ttm)
$119.71K
Revenue Growth
-26.75%
P/S Ratio
379.28
Revenue / Employee
$3,236
Employees
37
Market Cap
45.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
DXR News
- 6 weeks ago - Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal - GlobeNewsWire
- 6 weeks ago - Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems - GlobeNewsWire
- 7 weeks ago - Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology - GlobeNewsWire
- 7 weeks ago - Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance - GlobeNewsWire
- 2 months ago - Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions - GlobeNewsWire
- 2 months ago - Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025 - GlobeNewsWire
- 2 months ago - New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival - GlobeNewsWire
- 3 months ago - Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo - GlobeNewsWire